Since the first description of the treatment of scleroderma (systemic sclerosis [SSc]) by Carlos Curzio in 1753, which included warm milk and vapor baths, bleeding from the foot, and oral administration of small doses of quicksilver (1), until the most recent clinical trials of anti-transforming growth factor beta monoclonal antibodies and novel tyrosine kinase inhibitors (2-10), numerous medications have been used in treating this condition. Despite intense efforts to develop effective therapies, SSc remains the autoimmune rheumatic disease with the highest case-specific mortality
展开▼
